Ansipastobart Biosimilar Monoclonal Antibody (CD73) for Research

Cat No.: GMP-Bios-INN-1081

Anti-NT5E/CALJA/CD73 therapeutic antibody (Pre-made Ansipastobart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Ansipastobart (development code BR101) is a monoclonal antibody targeting CD73 (NT5E). It is developed by BioRay Pharm for advanced solid tumors. It is in Phase I clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1081-1mg 1mg 3090
GMP-Bios-INN-1081-10mg 10mg
GMP-Bios-INN-1081-100mg 100mg
GMP-Bios-INN-1081-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Ansipastobart biosimilar, Whole mAb, Anti-NT5E/CALJA/CD73 Antibody: Anti-CD73/NT5E/5'-nucleotidase/5'-NT therapeutic antibody
INN Name Ansipastobart
Target NT5E/CALJA/CD73
Format Whole mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Lambda
Highest_Clin_Trial (Jan '20) Phase-I
Est. Status Active
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2024
Year Recommended 2024
Companies BioRay Pharm
Conditions Approved na
Conditions Active Advanced Solid Tumors
Conditions Discontinued na
Production na
Development Tech na